PLOS ONE | https://doi.org/10.1371/journal.pone.0192068 March 9, 2018
Manuel pour les personnels impliqués dans la prise en charge pédiatrique du VIH
Brochure à l’intention des professionnels des structures de
soins ambulatoires ou institutionnels et du travail social auprès des malades et de leurs proches.
The Lancet Global Health 2016 Published Online August 30, 2016
http://dx.doi.org/10.1016/S2214-109X(16)30175-9
International Journal for Quality in Health Care, 2018, 30(9), 724–730
Promoting hand hygiene in a neonatal intensive care unit.
Guide d'accompagnement de la formation en ligne.
Accessed March 2019
Large File: 17 MB
Public Health & Primary Care / Research Article
Cogent Medicine (2018), 5: 1430197
Lefebvre et al., Cogent Medicine (2018), 5: 1430197 https://doi.org/10.1080/2331205X.2018.1430197
Plus de 2000 enfants meurent chaque jour des suites de traumatismes involontaires ou accidentels. Chaque année des dizaines de milliers d'autres sont hospitalisés pour des blessures qui les laissent souvent handicapés à vie.
Ce rapport conjoint de l'OMS et de l'UNICEF établit le premier b...ilan mondial des principales causes à l'origine des traumatismes involontaires touchant des enfants: les accidents de la route, les noyades, les brûlures, les chutes et les empoisonnements.
more
Ginebra, 14-16 de marzo de 2011
Orientations provisoires
25 janvier 2020
Ce document est la première édition des orientations relatives aux stratégies de lutte anti-infectieuse à mettre en œuvre en cas de suspicion d’infection par un nouveau coronavirus (2019-nCoV). Il a été adapté du document de l’OMS intitulé P...révention et lutte contre les infections lors de la prise en charge de cas probables ou confirmés d’infection par le coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV)(1), sur la base des connaissances actuelles de la situation en Chine et dans d’autres pays où des cas ont été identifiés, et de l’expérience acquise sur le syndrome respiratoire aigu sévère (SRAS)-CoV et le MERS-CoV (2).
more
Clinical care for severe acute respiratory infection: toolkit: COVID-19 adaptation
The Malawian government recently introduced cost-covering consultation fees for self-referral patients in tertiary public hospitals. Previously, patients received medicines free of charge in government-owned health facilities, but must pay elsewhere. Before the government implements a payment policy... in other areas of health care, it is important to investigate the prices, affordability and availability of essential medicines in Malawi.
more
The Asthma Control Questionnaire (ACQ)1 was developed and validated to measure the primary clinical goal of asthma management as identified by international guidelines. They indicate that to achieve good control, treatment should minimise day and night time symptoms, activity limitation, airway narr...owing and rescue bronchodilator use and thus reduce the risk of life-threatening exacerbations and long-term morbidity. The importance of including all aspects of control in the assessment of individual patients was emphasised by a recent factor analysis which showed that clinical asthma is composed of distinct components which are not closely correlated with each other.6 However, in some studies it may not be possible to collect airway calibre or short-acting β2-agonists data. Previous analysis of non-clinical trial data suggested that when ACQ scores are analysed as group data, the heterogeneity of the way in which individual patients present with inadequate control is lost in the estimation of the mean and the need to measure each individual component of asthma control may become unnecessary. In this analysis, ACQ data from a clinical trial was used to evaluate the measurement properties (reliability, responsiveness, validity and interpretability), of three shortened versions of the ACQ. In addition, we have examined whether the precision and accuracy of estimating the effect of the intervention on asthma control was maintained when the two questions concerning airway calibre and short-acting β2-agonists use were omitted from the trial analysis.
more
Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transforma...tive therapy - and therefore where needs are not being met. Therefore, this study aims to define gaps in access to CF treatment. The results show that a significant CF patient burden exists in countries where disease-modifying drugs are unavailable, and final figures are likely underestimates. This analysis shows the potential to improve rates of diagnosis and treatment for CF, so a higher percentage of patients receive the most effective triple combination treatment.
more